09:04 EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer’s study miss
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Largest borrow rate increases among liquid names
- Cassava announces Phase 3 ReThink-ALZ data did not meet co-primary endpoints
- Cassava Sciences put volume heavy and directionally bearish
- Cassava Sciences appoints Freda Nassif as Chief Commercial Officer
- Cassava Sciences call volume above normal and directionally bullish